You just read:

Cyteir Therapeutics Secures Additional $40.2 Million in Its Series B Financing and Doses First Patient in Phase 1/2 Study of First-in-Class RAD51 Inhibitor

News provided by

Cyteir Therapeutics

Oct 15, 2019, 07:30 ET